Page 9 - இந்தியன் காப்புரிமை அலுவலகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Newgen Software Technologies Limited granted patent for new invention

Newgen Software Technologies Limited granted patent for new invention
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Indian patent officeNewgen software technologiesNewgen software technologies ltdSoftware technologies limitedTime zoneIndian patent office governmentCollaborative signingPatents actUser deviceDigital rights managementஇந்தியன் காப்புரிமை அலுவலகம்நியூஜென் மென்பொருள் தொழில்நுட்பங்கள்நியூஜென் மென்பொருள் தொழில்நுட்பங்கள் லிமிடெட்மென்பொருள் தொழில்நுட்பங்கள் வரையறுக்கப்பட்டவைநேரம் ஸோந்காப்புரிமைகள் நாடகம்

Royal Enfield sichert neue Namen: Shotgun und Scram

Royal Enfield sichert neue Namen: Shotgun und Scram
motorradonline.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from motorradonline.de Daily Mail and Mail on Sunday newspapers.

United kingdomIndian patent officeMother groupNew namesVehicle manufacturer new namesPatent protectionAlready beginningPatent numberUnited kingdom militaryNew models orஒன்றுபட்டது கிஂக்டம்இந்தியன் காப்புரிமை அலுவலகம்அம்மா குழுபுதியது பெயர்கள்காப்புரிமை ப்ரொடெக்ஶந்காப்புரிமை எண்

Panacea Biotec files suit against Sanofi for patent infringement

Panacea Biotec files suit against Sanofi for patent infringement SECTIONS Last Updated: May 17, 2021, 02:48 PM IST Share Synopsis The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent vaccine by the Drugs Controller General (India), Panacea Biotec said in a regulatory filing. Reuters Panacea Biotec on Monday said it has filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare India from marketing a fully liquid hexavalent vaccine. The national capital-based firm said a case has been filed in order to stop infringement of its patent for fully liquid whole cell pertussis based fully liquid Hexavalent vaccine EasySix.

Indian patent officeDelhi high courtWhole cell pertussisDrugs controller generalDelhi high courtsWhooping coughPanacea biotecLiquid hexavalent vaccineDrugs controllerஇந்தியன் காப்புரிமை அலுவலகம்டெல்ஹி உயர் நீதிமன்றம்மருந்துகள் கட்டுப்படுத்தி ஜநரல்டெல்ஹி உயர் நீதிமன்றங்கள்ஹூப்பிங் இருமல்சஞ்சீவி பயோடெக்மருந்துகள் கட்டுப்படுத்தி

Natco Pharma signs licensing agreement with Eli Lilly

Natco Pharma signs pact with Eli Lilly for COVID drug in India

The drug maker signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for COVID-19 indication in India. In line with the licensing agreement, Natco Pharma has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for COVID-19 in India. Natco Pharma had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Eli lillyNatco pharmaIndian patent officeCentral drugs standard control organizationCompulsory licenseCapital marketChemical compoundsHealth sciencesOrganic compoundsBreakthrough therapyEli lilly and companyPharmaceutical industryEli lillyRoyalty paymentHarmaceuticals necCentral drugs